Skip to main content
Oregon.gov Homepage

Oregon Psilocybin Services Act (Measure 109)

Sign up for Updates

Measure 109 Implementation

Ballot Measure 109 (2020) directs the Oregon Health Authority (OHA) — after a two-year development period from January 1, 2021 to December 31, 2022 — to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products and the provision of psilocybin services. During the two year development period OHA will work with the Oregon Psilocybin Advisory Board to establish rules and regulations implementing Measure 109 and the use of psilocybin products and services.

OHA will not be issuing licenses or accepting applications related to the manufacture, sale and purchase of psilocybin products and the provision of psilocybin services until January 2, 2023.

Email inquiries: oha.psilocybin@dhsoha.state.or.us

Read Measure 109 - The Oregon Psilocybin Services Act

Oregon Psilocybin Advisory Board

Established by Ballot Measure 109 (2020), the Oregon Psilocybin Advisory Board makes recommendations to OHA on available scientific studies and research on the safety and efficacy of psilocybin in treating mental health conditions, and makes recommendations on the requirements, specifications and guidelines for providing psilocybin services in Oregon. The Board will also develop a long-term strategic plan for ensuring that psilocybin services will become and remain a safe, accessible and affordable therapeutic option for all persons 21 years of age and older in this state for whom psilocybin may be appropriate; and monitor and study federal laws, regulations and policies regarding psilocybin.

Advisory Board Meetings

March 31, 2021, 1:00 - 4:00 pm 
Meeting Minutes 
An audio link to the entirety of the March 31 meeting is available below: 
Complete PAB Meeting 3.31.21.m4a

April 28, 2021, 1:00 - 4:00 pm
Complete PAB Meeting 4.28.21.m4a

May 26, 2021, 1:00 - 4:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Subcommittee Meetings

Training Subcommittee

April 23, 2021, 1:00 - 3:00 pm 
Complete PAB-TS Meeting 4.23.21.m4a

May 7, 2021, 1:00 - 3:00 pm

Meeting Agenda
Complete PAB-TS Meeting 5.7.21.m4a

May 14, 2021, 1:00 - 3:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728 


Research Subcommittee 

April 14, 2021 

Meeting Notes 

Powerpoint

Complete PAB-RS Meeting 4.14.21.m4a

April 29, 2021 

Meeting Notes

Complete PAB-RS Meeting 4.29.21.m4a

May 6, 2021, 1:00-2:00 pm

https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Meeting Notes 
Complete PAB-RS Meeting 5.6.21.m4a


May 13, 2021, 1:00 - 2:00 pm

https://www.zoomgov.com/j/16018821728

Meeting ID: 160 1882 1728
Meeting Agenda

May 20, 2021, 1:00 - 2:00 pm

https://www.zoomgov.com/j/16018821728

Meeting ID: 160 1882 1728

May 27, 2021, 1:00 - 2:00 pm

https://www.zoomgov.com/j/16018821728

Meeting ID: 160 1882 1728

June 3, 2021, 1:00 - 2:00 pm

https://www.zoomgov.com/j/16018821728

Meeting ID: 160 1882 1728


Products Subcommittee 

May 14, 2021, 3:00-5:00 pm 
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Meeting Agenda (draft 5/7/21)  


Licensing Subcommittee

May 13, 2021 2:00 - 4:00 pm

https://www.zoomgov.com/j/16018821728

Meeting ID 160 1882 1728


Equity Subcommittee

May 12, 2021 4:00 - 5:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Meeting Agenda 









Scientific Literature Review

Safety and efficacy of psilocybin in treating mental health conditions

By June 30, 2021, the board will submit its findings and recommendations to the Oregon Health Authority on the available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress. 

By July 31, 2021, and from time to time after such date, the Oregon Health Authority shall publish and distribute to the public available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end of-life psychological distress.


Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how

×